Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 14, 2025
Targeting acute myeloid leukemia resistance with two novel combinations demonstrate superior efficacy in TP53, HLA-B, MUC4 and FLT3 mutationsElham Gholizadeh, Ehsan Zangene, Alun Parsons, et al.
Scientific Reports|December 8, 2021
FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AMLJarno Kivioja, Disha Malani, Ashwini Kumar, et al.
Journal of Internal Medicine|August 8, 2025
Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatmentsMartin Jädersten, Ingrid Lilienthal, Christer Nilsson, et al.
Scientific Reports|May 14, 2025
CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignanciesSofia Aakko, Arno Ylitalo, Heikki Kuusanmäki, et al.
Leukemia|July 12, 2020
Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibitionMahesh Tambe, Ella Karjalainen, Markus Vähä-Koskela, et al.
Blood Advances|January 10, 2024
Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemiaSamuli Eldfors, Joseph Saad, Nemo Ikonen, et al.
Cell Death & Disease|October 16, 2024
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidineMahesh Tambe, Sarah Unterberger, Mette C Kriegbaum, et al.
Leukemia & Lymphoma|August 5, 2017
Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemiaJarno L Kivioja, Jesus M Lopez Martí, Ashwini Kumar, et al.
Leukemia|December 21, 2018
Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemiaJarno L Kivioja, Angeliki Thanasopoulou, Ashwini Kumar, et al.
The Lancet. Haematology|May 31, 2025
Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trialMika Kontro, Anthony Selwyn Stein, Marja Pyörälä, et al.
Pageof 4